Chongqing Lummy Pharmaceutical Co Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Chongqing Lummy Pharmaceutical Co Ltd with three other
companies in this sector in China:
Sinovac Biotech Ltd
sales of 1.17 billion Chinese Renmimbi [US$171.47 million]
of which 70%
was Enterovirus 71 vaccines),
Hybio Pharmaceutical Co Ltd
(1.25 billion Chinese Renmimbi [US$181.99 million]
of which 100%
was Medical and Pharmaceutical Manufacturing), and
Jilin Zixin Pharmaceutical Industrial Co Ltd
(1.33 billion Chinese Renmimbi [US$193.82 million]
of which 54%
During the year ended December of 2017, sales at
Chongqing Lummy Pharmaceutical Co Ltd were 1.28 billion Chinese Renmimbi (US$187.22 million).
increase of 29.5%
versus 2016, when the company's sales were 990.18 million Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Chongqing Lummy Pharmaceutical Co Ltd
(and since 2012, sales have increased a total of 103%).
Sales of Other Operations saw an increase
that was more than double the company's growth rate: sales were up
255.2% in 2017, from
1.15 million Chinese Renmimbi to 4.09 million Chinese Renmimbi.
Not all segments of Chongqing Lummy Pharmaceutical Co Ltd experienced an increase in sales in 2017:
sales of Chemical Distribution fell 71.1% to 5.56 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).